Table 3. Summary of studies showing freedom from biochemical relapse after high dose rate (HDR) brachytherapy combined with external beam radiotherapy (EBRT), according to risk group.
Reference | Dose schedule | No. of patients | Low risk (%) | Intermediate risk (%) | High risk (%) | End point (years) |
Aström et al [34] | EBRT: 50 Gy @ 2 Gy per fraction | 214 | 100 | 100 | 86 | 4 |
HDR: 2×10 Gy per fraction | ||||||
Flynn et al [38] | NAHT: 86% | 674 | 97 | 92 | 72 | 5 |
EBRT: 45 Gy @ 1.8 Gy per fraction | ||||||
HDR: 15.5–21.0 Gy in 3 or 4 fractions | ||||||
Galalae et al [33] | EBRT: 45.6−50.0 Gy @ 1.8–2.0 Gy per fraction | 611 | 96 | 88 | 69 | 5 |
HDR: BED 79.6–123.0 Gy | ||||||
Galalae et al [39] | NAHT: 0% | 324 | – | 85 | 81 | 5 |
BED: <94 Gy vs >94 Gy | ||||||
Guix et al [41] | EBRT: 46–66 Gy @ 2 Gy per fraction | 445 | – | 95 | 94 | 5 |
HDR: 2×5–8 Gy | ||||||
Izard et al [43] | NAHT: median 6 months | 165 | 100 | 95 | 67 | 5 |
EBRT: 45.0–59.4 Gy @ 1.8 Gy per fraction | ||||||
PDR BRT: 18 Gy in 3 fractions | ||||||
Martinez et al [44] | NAHT: no | 207 | – | 85 | 75 | 5 |
HDR: 5.5–11.5 Gy per fraction | ||||||
Phan et al [46] | NAHT: 36% | 309 | 100 | 100 | 97 | 5 |
EBRT: 36.0–50.4 @ 1.8–2.0 Gy per fraction | ||||||
HDR: 22–24 Gy | ||||||
Yamada et al [47] | EBRT: 45.0–50.4 Gy @ 1.8 Gy per fraction | 105 | 100 | 98 | 92 | 5 |
HDR: 5.5–7.0 Gy in single fraction | ||||||
Pellizzon et al [45] | EBRT: 45 Gy median | 209 | 91 | 90 | 89 | 5 |
HDR: 20 Gy median | ||||||
Agoston et al [36] | EBRT: 60 Gy median | 280 | – | 84 | 82 | 5 |
HDR: 10 Gy in single fraction | ||||||
Demanes et al [37] | NAHT: no | 209 | 93 | 82 | 62 | 10 |
EBRT: 36 Gy @ 1.8 Gy per fraction | ||||||
HDR: 22–24 Gy in 4 fractions | ||||||
Ghilezan et al [40] | NAHT: 43% | 1577 | – | 88 | 74 | 10 |
EBRT: 40 Gy median | ||||||
HDR: 24 Gy median | ||||||
Hasan et al [42] | 886 | 98 | 92 | 71 | 10 |
BED, biologically equivalent dose; NAHT, neoadjuvant hormone therapy; PDR, pulse dose rate brachytherapy.